Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?

Moderna's market capitalization is near $90 billion after its shares gained more than 660% year to date on Phase 3 results for its personalized melanoma vaccine, while BioNTech's market cap is below $25 billion after its colorectal cancer vaccine failed to show efficacy in a Phase 2 study. The article favors BioNTech at current valuations: 11 of 15 analysts rate it a buy, with roughly 30% implied upside, versus just 3 buys among 20 Moderna analysts and an average target 52.5% below its Oct. 9, 2026 closing price. BioNTech had about $18.6 billion in cash at Q2-end, while the article flags uncertainty from its founders' planned departure and says Moderna trades above 32 times sales versus BioNTech at 8 times.

Analysis

The key mispricing risk is treating one successful melanoma program as proof of a repeatable Moderna oncology platform—and one ineffective BioNTech trial as proof that its broader pipeline is impaired. The former can support a premium only if mature follow-up confirms durable clinical benefit and the Merck collaboration leaves Moderna meaningful economics; endpoint quality, regulatory path, and commercial rights matter more than headline response data. Merck may participate in upside, but the size is unquantifiable without the agreement’s economics.

BioNTech’s lower valuation and reported cash cushion provide downside support, not a floor: the failed study raises the hurdle for other tumor-specific programs, while founder departures introduce execution and talent-retention risk. The valuation gap could therefore persist even if the market has over-penalized the company. Analyst targets are a weak anchor, particularly after a sharp re-rating and before pivotal evidence is fully assessed.

Near term, clinical updates and leadership-transition details can dominate fundamentals. Over 1–3 months, watch for fuller Moderna efficacy/safety data and BioNTech pipeline readouts or governance disclosures. Over 6–18 months, the question is whether either company converts platform promise into repeatable, economically attractive products. A relative-value position is preferable to an outright short because positive oncology data can gap either stock.

Key Decisions for Investors

• Consider a small, staged long BNTX / short MRNA relative-value position, preferably with defined-risk options rather than an unhedged short. Do not size it from the article’s analyst targets; confirm current valuation, cash burn, pipeline catalysts, and Moderna’s collaboration economics first.
• Avoid chasing MRNA after its re-rating. Reassess after detailed pivotal-trial data: durable benefit, acceptable safety, and a credible regulatory path would invalidate the short leg; weaker follow-up or unclear commercial economics would strengthen it.
• Treat BNTX as a watchlist value setup, not a cash-backed floor. Reduce or exit the long if subsequent trials show broader efficacy problems, cash burn materially accelerates, or founder departures lead to meaningful pipeline delays.
• Before entry, verify trial endpoints and follow-up, the Merck–Moderna profit-sharing terms, BioNTech’s latest unrestricted cash and burn, and leadership-transition arrangements. Without these, keep exposure small or wait.